Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment–Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention

Sources of Funding, see page 2326 BACKGROUND: Early treatment with a potent oral platelet P2Y12 inhibitor is recommended in patients presenting with ST-segment–elevation myocardial infarction scheduled to undergo primary percutaneous coronary intervention (pPCI). The impact on coronary reperfusion of crushed P2Y12 inhibitor tablets, which lead to more prompt and potent platelet inhibition, is unknown.

[1]  A. Messori,et al.  Letter by Ferracane et al Regarding Article, "Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials". , 2021, Circulation.

[2]  Correction to: Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial. , 2020, Circulation.

[3]  M. Valgimigli,et al.  Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. , 2020, Journal of the American College of Cardiology.

[4]  M. Krucoff,et al.  COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial. , 2020, American heart journal.

[5]  W. Rottbauer,et al.  Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. , 2019, The New England journal of medicine.

[6]  Marco Valgimigli,et al.  Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. , 2019, JACC. Cardiovascular interventions.

[7]  L. Been,et al.  Effects of the Peripheral Opioid Receptor Antagonist Methylnaltrexone on the PK and PD Profiles of Ticagrelor in Patients With Coronary Artery Disease Treated With Morphine. , 2019, JACC. Cardiovascular interventions.

[8]  Yaiza Beatriz Molero-Díez,et al.  Fourth universal definition of myocardial infarction , 2019, Colombian Journal of Anesthesiology.

[9]  L. Been,et al.  Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of the CANTIC Study , 2019, Circulation.

[10]  P. Seferovic,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[11]  D. Angiolillo,et al.  Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use , 2019, Therapeutic advances in cardiovascular disease.

[12]  G. Levine,et al.  ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison. , 2018, Journal of the American College of Cardiology.

[13]  M. Marszałł,et al.  METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectorIS—The METAMORPHOSIS Trial , 2018, Thrombosis and Haemostasis.

[14]  E. Iliodromitis,et al.  Cangrelor in Ticagrelor-Loaded STEMI Patients Undergoing Primary Percutaneous Coronary Intervention. , 2018, Journal of the American College of Cardiology.

[15]  Kristian Thygesen,et al.  Fourth Universal Definition of Myocardial Infarction (2018). , 2018, Journal of the American College of Cardiology.

[16]  G. Hindricks,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[17]  L. Bonello,et al.  Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. , 2017, Archives of cardiovascular diseases.

[18]  D. Angiolillo,et al.  Antithrombotic therapy for patients with STEMI undergoing primary PCI , 2017, Nature Reviews Cardiology.

[19]  Won Young Kim.  Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study. , 2017, Journal of the American College of Cardiology.

[20]  D. Angiolillo,et al.  Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients , 2016, Expert review of cardiovascular therapy.

[21]  D. Angiolillo,et al.  Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation. , 2015, JACC. Cardiovascular interventions.

[22]  D. Angiolillo,et al.  Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era: Review of the Evidence and Practice Guidelines , 2015, Circulation. Cardiovascular interventions.

[23]  R. Abbate,et al.  Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. , 2015, Journal of the American College of Cardiology.

[24]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In , 2014, JACC. Cardiovascular interventions.

[25]  I. Xanthopoulou,et al.  Onset of Antiplatelet Action With High (100 mg) Versus Standard (60 mg) Loading Dose of Prasugrel in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Pharmacodynamic Study , 2014, Circulation. Cardiovascular interventions.

[26]  G. Schuler,et al.  Association of upstream clopidogrel administration and myocardial reperfusion assessed by cardiac magnetic resonance imaging in patients with ST-elevation myocardial infarction , 2014, European heart journal. Acute cardiovascular care.

[27]  R. Abbate,et al.  Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. , 2013, Journal of the American College of Cardiology.

[28]  Gregg W Stone,et al.  Effect of platelet inhibition with cangrelor during PCI on ischemic events. , 2013, The New England journal of medicine.

[29]  I. Xanthopoulou,et al.  Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment–Elevation Myocardial Infarction , 2012, Circulation. Cardiovascular interventions.

[30]  Deepak L. Bhatt,et al.  Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials , 2012, Journal of Thrombosis and Thrombolysis.

[31]  R. Ferrari,et al.  Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients wit , 2012, JACC. Cardiovascular interventions.

[32]  E. Braunwald,et al.  A tale of coronary artery disease and myocardial infarction. , 2012, The New England journal of medicine.

[33]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[34]  D. Ardissino,et al.  Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis , 2010, Circulation.

[35]  R. Ferrari,et al.  Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. , 2010, Journal of the American College of Cardiology.

[36]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[37]  J. Ottervanger,et al.  Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial , 2008, The Lancet.

[38]  H. Losert,et al.  Platelet Function Predicts Myocardial Damage in Patients With Acute Myocardial Infarction , 2004, Circulation.

[39]  G. Montalescot,et al.  Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. , 2004, JAMA.

[40]  M. Morice,et al.  Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. , 2001, The New England journal of medicine.

[41]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[42]  G. Montalescot,et al.  Prehospital ticagrelor in ST-segment elevation myocardial infarction. , 2014, The New England journal of medicine.

[43]  F. Verheugt,et al.  Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. , 2008, Thrombosis research.

[44]  R. Ferrari,et al.  CLINICAL RESEARCH Interventional Cardiology Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention Insights Into the STRATEGY Study , 2006 .